FAQ on NanoViricides' NV-387 Antiviral Potential and Pandemic Preparedness

What is NV-387 and what viruses does it target?

NV-387 is a broad-spectrum antiviral nanomedicine candidate developed by NanoViricides, Inc., showing promising effectiveness against viruses including MPox, Smallpox, Measles, Influenza, and Coronaviruses.

Why is NV-387 significant in the context of pandemic preparedness?

NV-387’s broad-spectrum antiviral effectiveness and potential for shared development costs across indications make it a strategic asset in global pandemic preparedness efforts, addressing a rapidly growing multi-billion-dollar market.

What are the next steps for NV-387’s development?

NanoViricides plans to launch a Phase II trial for MPox, which could position NV-387 as the first approved treatment for the virus, with potential orphan drug designations and eligibility for priority review vouchers.

How does NanoViricides’ business model work?

NanoViricides’ business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, focusing on developing broad-spectrum antiviral drugs like NV-387.

What other drug candidates does NanoViricides have?

Besides NV-387, NanoViricides is developing NV-HHV-1 for Shingles treatment and NV-CoV-2 and NV-CoV-2-R for COVID-19, with NV-387 also being considered for RSV, Long COVID, and other respiratory viral infections.

When can we expect NV-387 to be available?

NanoViricides cannot project an exact date for filing an IND for NV-387 due to dependence on external collaborators and consultants, but is currently focused on advancing it into Phase II human clinical trials.

Where can I find more information about NanoViricides and NV-387?

For more information about NanoViricides and its drug candidates, visit www.NanoViricides.com or check the latest updates in the company’s newsroom at https://ibn.fm/NNVC.

What are the potential benefits of NV-387 for investors?

NV-387 offers potential early revenues and strategic value in pandemic preparedness, with shared development costs across indications and eligibility for priority review vouchers, targeting a multi-billion-dollar market.